Dren Bio Logo

Robust depletion of disease-causing cells and agents

Dren’s team has profound expertise in antibody executed elimination of pathological cells


We selectively engage an effector cell for targeted depletion of diseased cells or agents

The company’s pipeline has two lead programs:

dren's targetDR-01 utilizes antibody-mediated killing of a cell type involved in leukemia, lymphomas and autoimmune diseases


  • dren's targetInitially targeting neglected HemOnc indications with no approved therapies

  • dren's targetExpansion into defined subsets of autoimmune diseases

monocyte cell

dren's targetDR-02 is an enhanced antibody-based platform for depletion of cells and disease-inducing agents through a novel MOA


  • dren's targetPotential applications in solid tumors, hematologic neoplasms, infectious diseases and protein aggregate diseases

  • dren's targetA proprietary monotherapy with multiple modes of action

    • dren's targetDirect depletion
    • dren's targetImmune stimulation
    • dren's targetTarget engagement
    • dren's targetAntigen presentation

Leadership

Board of Directors and Investors

Alexandria Venture Investments

Scientific Advisory Board

Careers

Senior Scientist I, Analytical and Formulation Development


About the Company:

Dren Bio (the “Company”) is a privately held, pre-clinical stage biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseases. The Company’s management team and scientific advisors have profound expertise covering the discovery and development of engineered antibodies designed to selectively target and deplete pathological cells. Dren Bio’s pipeline is currently comprised of two distinct programs. The first program surrounds DR-01, the Company’s lead product candidate, which induces antibody-mediated killing of a cell type that is responsible for a multitude of hematologic malignancies and plays a key role in various autoimmune diseases. The Company’s second program is a proprietary antibody-based technology platform, its Targeted Myeloid Engager, which utilizes a novel mechanism of action to selectively engage myeloid cells for the targeted depletion of diseased cells and disease-inducing agents, as well as to induce immunostimulation.

Function:

Analytical and Formulation Development and Drug Product Manufacturing

Level:

Senior Scientist I

Location:

Redwood City, CA

Reporting Manager:

Director, Analytical and Formulation Development

About the Opportunity:

Dren Bio is seeking a highly motivated individual to support antibody characterization and formulation development for the Company’s pipeline programs. The successful candidate will work as a bench Scientist to conduct analytical method and formulation development and be involved in interactions with contract development and manufacturing organizations (CDMOs). This position offers excellent potential for contribution and visibility at an early-stage company and opportunities for career development.

Role and Responsibilities:
  • Develop HPLC, capillary electrophoresis and ELISA based analytical methods for protein/antibody characterization.

  • Serve as investigative lead on antibody/bispecific programs with respect to analytical methods (including but not limited to RP-HPLC, Ion exchange, Capillary electrophoresis, SE-HPLC and HIC).

  • Apply scientific principles, current technologies, and personal experience to design and execute appropriate experiments to solve a given problem.

  • Work closely with colleagues in Process Sciences group to ensure timely analytical support for cell line, process, and formulation development.

  • Partner with discovery/biology groups to establish process and criteria for manufacturability assessments for clinical candidates at discovery stage.

  • Contribute to authoring/reviewing CMC sections in IND/CTA submissions and BLA/MAA submissions; includes developing comparability strategies and performing CQA assessments.

  • Facilitate the development of SOPs for various analytical methods and the qualification of methods required for technical transfer to CDMO/CRO facilities.

  • Maintain and troubleshoot analytical instrumentation as required and troubleshoot assay performance as needed.

  • Supervise and mentor junior staff with analytical development activities when appropriate.

  • Independently evaluate literature to identify and implement new analytical tools and methodologies as part of continuous improvement.

  • Document experimental work in notebooks, SOPs and reports.

  • Communicate results and provide updates at internal and external project team meetings.

Education, Experience and Qualification Requirements:
  • PhD in Biochemistry, Analytical Chemistry or related discipline with approximately 5+ years of experience in the biotechnology industry.

Core Competencies, Knowledge and Skill Requirements:
  • Hands-on knowledge of technical scientific principles for most of the following analytical techniques: HPLC/UPLC (reverse phase, ion exchange, size exclusion), capillary electrophoresis; working knowledge of LC/MS is highly desirable.

  • Strong analytical and critical thinking skills with the ability to interpret complex data and highly motivated to learn and support the drug development efforts.

  • Ability to manage and mentor junior staff in method development work; previous supervisory experience preferred.

  • Experience with performing developability or manufacturability assessments for therapeutic candidates is desirable.

  • Motivated self-starter who can work independently and collaboratively in a dynamic team environment with a proactive attitude.

  • Excellent written and verbal communication skills.

  • Ability to work in a fast-paced environment and the flexibility to align daily work with project needs.

  • Ability to set goals and prioritize tasks and resources to achieve superior work quality and efficiency.

  • Must be well organized, have a strong work ethic, attention to detail and be diligent in data documentation.

Salaries, Benefits and Other Employee Perks:

Dren Bio strongly believes in investing in, and rewarding, its employees. This philosophy is embodied in the Company’s total rewards program, which includes competitive cash compensation, equity incentive awards, and employer sponsored benefit offerings. Exact cash and equity compensation shall be commensurate with candidate’s experience and qualifications.

Employment Practices:

Dren Bio is an equal opportunity employer. Employment decisions are based on merit and business needs. Dren Bio will not discriminate against any job applicant because of race, color, national origin, ancestry, gender, sexual orientation, age, religion, creed, physical or mental disability, gender identity, medical condition, pregnancy, marital status, veteran status, or any other characteristic protected by federal, state or local law..

Interested Applicants:

Please send resume and cover letter to cmc_careers@drenbio.com.

PDF Version

Senior Manager, CMC Project Management


About the Company:

Dren Bio (the “Company”) is a privately held, pre-clinical stage biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseases. The Company’s management team and scientific advisors have profound expertise covering the discovery and development of engineered antibodies designed to selectively target and deplete pathological cells. Dren Bio’s pipeline is currently comprised of two distinct programs. The first program surrounds DR-01, the Company’s lead product candidate, which induces antibody-mediated killing of a cell type that is responsible for a multitude of hematologic malignancies and plays a key role in various autoimmune diseases. The Company’s second program is a proprietary antibody-based technology platform, its Targeted Myeloid Engager, which utilizes a novel mechanism of action to selectively engage myeloid cells for the targeted depletion of diseased cells and disease-inducing agents, as well as to induce immunostimulation.

Function:

CMC Project Management

Level:

Senior Manager

Location:

Redwood City, CA

Reporting Manager:

Executive Vice President, Process Sciences and Manufacturing Operations

About the Opportunity:

Dren Bio is seeking a highly motivated individual to support CMC project management for the Company’s pipeline programs. The successful candidate will manage internal and outsourced CMC activities for specified projects at all development stages and be involved in interactions with contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). This position offers excellent potential for contribution and visibility at an early-stage company and opportunities for career development.

Role and Responsibilities:
  • Lead CMC team organizational meetings and ensure clear agendas are set, actions and decisions are documented and communicated to meet CMC project timelines.

  • Serve as the primary point of contact for CMC project management activities internally and externally with CDMOs and CROs. This includes activities such as cell line development, drug substance/drug product manufacturing, labeling/packaging, and distribution for clinical studies. Proactively track and manage activities at CDMOs and CROs, and facilitate resolution of issues to keep project activities on track.

  • Maintain frequent communication with the cross-functional CMC project team members and key internal stakeholders so that all parties are aware of current project status, issues, contingencies, and milestones.

  • Ensure that management and teams are kept apprised of progress against plans, and changes. Regularly communicate project status including expectations, opportunities and risks via written communication as well as presentations, discussions and informal interactions.

  • Ensure project plans and objectives are clearly established and communicated. Create timelines and utilize planning tools such as decision support models and Gantt charts. Work with other project managers to integrate CMC timelines and deliverables with the overall project plans.

  • Proactively identify CMC critical path activities, risks and impediments to successful development and work within the team to identify solutions to mitigate these risks.

  • Build strong working relationships across departments and with key stakeholders to ensure transparency and to facilitate communication.

  • Coordinate preparation and review of CMC regulatory filings.

  • Create purchase orders, invoice tracking/payments, accruals and reforecasting on a quarterly basis.

  • Some US and international travel required.

Education, Experience and Qualification Requirements:
  • BA/BS in or higher degree in life sciences, chemistry, engineering, or equivalent related discipline with 8-10 years of experience in the biopharmaceutical industry including CMC project management experience. Prior technical experience in process development/CMC area is required. PMP certification preferred.

Core Competencies, Knowledge and Skill Requirements:
  • Demonstrated experience with CMC operational efforts on biologic products.

  • Technical experience in CMC development of a biologic product required.

  • Proven ability to manage competing priorities, budgets, and timelines in a fast-paced, rapid-growth environment.

  • Highly skilled at working collaboratively with cross-functional teams and contractors to drive results and meet company objectives.

  • Ability to distill, organize, and effectively communicate (verbal and written) key messages from complex discussions.

  • Self-directed and proactive with ability to function independently in certain situations, exercise good judgment and respond quickly and effectively to changing environments.

  • Ability to deal with uncertainty, unanticipated challenges in a constructive manner and generate options for moving forward.

  • Demonstrated ability to utilize project management tools successfully; strong computer skills and experience with software such as MS Project, Excel, SharePoint.

  • Adequate knowledge of cGMP, US and EU regulations.

  • Experience working with CMC teams and managing relationships with CMOs/CROs is preferred.

  • In-depth knowledge of some aspects of the biopharmaceutical industry, drug development (ex. cell line development, process/analytical development, manufacturing, drug substance/drug product, formulation and regulatory approval process) is preferred.

  • Early-stage clinical development and IND experience is preferred.

Salaries, Benefits and Other Employee Perks:

Dren Bio strongly believes in investing in, and rewarding, its employees. This philosophy is embodied in the Company’s total rewards program, which includes competitive cash compensation, equity incentive awards, and employer sponsored benefit offerings. Exact cash and equity compensation shall be commensurate with candidate’s experience and qualifications.

Employment Practices:

Dren Bio is an equal opportunity employer. Employment decisions are based on merit and business needs. Dren Bio will not discriminate against any job applicant because of race, color, national origin, ancestry, gender, sexual orientation, age, religion, creed, physical or mental disability, gender identity, medical condition, pregnancy, marital status, veteran status, or any other characteristic protected by federal, state or local law..

Interested Applicants:

Please send resume and cover letter to cmc_careers@drenbio.com.

PDF Version

News

Dren Bio announces a $60M Series A financing

2020-10-16

SAN CARLOS, CA,


Dren Bio, Inc., a company developing powerful protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, announced the closing of a $60 million Series A investment round. The round was led by SR One and Taiho Ventures, LLC , with participation from existing investors 8VC and Mission BioCapital and new investors including BVF Partners L.P., HBM Healthcare Investments, and Alexandria Venture Investments.

Dren will utilize the proceeds to advance its two lead programs through early clinical development. Dren’s first program, DR-01, is an antibody-based therapy to treat rare leukemias and lymphomas as well as specific phenotypes of auto-immune disorders. Dren’s second program, DR-02, is an enhanced antibody-based platform to deplete cells and other disease-causing agents through a novel mechanism-of-action.

"Our strategy is to select the appropriate immune cell type to induce potent and measurable therapeutic effects," said Nenad Tomasevic, PhD, Dren’s Chief Executive Officer and co-founder. "The DR-01 program employs enhanced ADCC to eliminate pathologic cells in clearly defined patient populations. Our DR-02 platform engages a different immune effector cell to a target, resulting in immune stimulation and target depletion."

Dr. Tomasevic brings over twenty years of biotech development experience and previously co-founded Allakos, a clinical-stage, publicly-traded company nearing commercialization.

Lewis Lanier, PhD, Chair of Dren’s Scientific Advisory Board, said, "Dren’s therapies are exciting because they offer novel strategeies to meet an unmet need in treatment of lymphomas and leukemias and to potentially enhance the potency of T cells in cancer immunotherapy." Dr. Lanier is the Chair of Microbiology and Immunology and the J. Michael Bishop MD Distinguished Professor at UCSF.

"We are impressed by Dren’s progress since the company’s inception in 2019," commented Rajeev Dadoo, Partner at SR One. "The DR-01 program has a clear development path to the clinic, focusing on diseases with no approved therapies."

"In oncology, the DR-02 platform could enable direct and selective depletion of cancer cells accompanied by localized immune stimulation," said Sakae Asanuma, President at Taiho Ventures. "The technology is also demonstrating the potential to eliminate agents in diverse diseases, including infections and protein aggregation. We are proud to recognize Dren’s potential at an early stage and support its success."

Dren previously closed a $6 million Seed Financing in 2019 led by 8VC with participation by Mission BioCapital and prominent industry veterans. "We appreciate the support from Dren’s investors,who to date have committed over $66 million in funding for our programs," said John Wesley, co-founder and Chief Financial Officer. "The goal of our Series A financing is to bring two drug candidates to the clinic."

About Dren Bio:

Dren Bio is a San Carlos, CA based biotechnology company developing powerful protein engineering technologies to deplete cells, protein aggregates and other disease-causing agents. Dren’s lead programs are initially focused on hematologic neoplasms and solid cancers. Dren is actively working in other areas including auto-immune disorders and diseases of protein aggregation. Dren’s team includes accomplished research and development personnel with strong collective industry experience. For more information, please visit: https://drenbio.com/.

About SR One

SR One invests globally in emerging life science companies pursuing innovative science to significantly impact medical care. SR One’s team of investment professionals, located in the US and UK, have experience spanning basic science, drug development and commercialization. For more information, please visit: http://www.srone.com/

About Taiho Ventures

Taiho Ventures, LLC is the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharma focusing on oncology, allergy and immunology, and urology. Taiho Ventures is looking at early-stage preclinical oncology companies as well as platform technology companies for our core therapeutic areas. Taiho Ventures will review the wide variety of modalities for both biologics and small molecules and also consider the option type of investments and spin-outs, in addition to the pure equity investments. For more information, please visit: https://www.taihoventures.com/

About 8VC

8VC is a leading technology investment firm investing in visionary teams and backing industry-transforming companies. The partners have a proven track-record as founders, engineers, and operators of successful companies including Palantir, Addepar, Affinity and OpenGov, among others. The predecessor firm Formation 8 was founded in 2012 and today, manages $1.1 billion in committed capital. 8VC was founded in 2016 and manages $2.4 billion in committed capital. 8VC invests primarily in SaaS companies and biotechnology. For more information, please visit http://8vc.com.

About BVF Partners L.P.

BVF Partners L.P. is a San Francisco-based investment management firm with more than 26 years investing in public and private biotechnology companies. For more information, please visit: https://www.bvflp.com/

About HBM Healthcare Investments

HBM Healthcare Investments holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN). For more information, please visit: https://www.hbmhealthcare.com/

About Mission BioCapital

Mission BioCapital (MBC) brings together the teams of Mission Bay Capital and BioInnovation Capital into a single venture firm. MBC is focused on making pivotal, early-stage investments in life science companies. We support entrepreneurs through a unique combination of shared lab spaces, capital investment and access to strategic partners. https://www.missionbiocapital.com/

About Alexandria Venture Investments

Alexandria Venture Investments, founded in 1996, is the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE:ARE). With more than $1B under management, Alexandria Venture Investments has been recognized by Silicon Valley Bank as the #1 most active investor in biopharma by new deal volume since 2017. Alexandria Venture Investments provides long-term strategic investment capital to transformative seed-, early- and growth-stage life science, technology and agtech companies advancing innovative platforms to improve human health. For more information, please visit www.are.com/venture-investments.html.

CONTACT: Nalin Sar

Dren Bio, Inc.

nsar@drenbio.com

info@drenbio.com

PDF Version

Contact

Map of California

Address

400 Seaport Ct, Ste 102, Redwood City, CA 94063


Email Address

info@drenbio.com